Cell Cycle
Cell Cycle is a peer-reviewed journal of cell biology, founded in 2002 by Landes Bioscience in Texas and now published by Taylor & Francis, appearing every two weeks. It positions itself on the fast publication of high-priority research, and its editorial board includes several Nobel laureates.《细胞周期》（Cell Cycle）是一份聚焦细胞生物学的同行评审学术期刊，二〇〇二年由兰德斯生物科学出版社创办于美国得克萨斯州，现由泰勒-弗朗西斯（Taylor & Francis）出版，每两周一期。该刊以「快速发表高优先级研究」自我定位，编委会中包含多位诺贝尔奖得主。
Scope
Cell Cycle takes the full span of cell biology as its territory, its official profile running from yeast to man and from DNA to function, a breadth unusual among cell-biology titles. Its principal subject areas include:Cell Cycle 的取稿立场是「从酵母到人、从脱氧核糖核酸到功能」的全链条细胞生物学，官方简介以排比句式列出其覆盖跨度，边界之宽在细胞生物学刊物中相当突出。收文范围覆盖的主要方向包括：
- Cycle regulation and checkpoints: cell-cycle regulation, checkpoints and the DNA damage response, the journal's traditional core.周期调控与检查点： 细胞周期调控、检查点与损伤应答，是该刊的传统核心方向。
- Cell death: the molecular basis and regulation of the different modes of cell death.细胞死亡： 各类细胞死亡机制的分子基础与调控。
- Non-coding RNAs: the regulation of the cell cycle by non-coding RNAs and their roles in disease.非编码核糖核酸： 非编码核糖核酸对细胞周期的调控及其在疾病中的角色。
- Ageing and metabolism: ageing, reproductive medicine and neurological health, together with cardiovascular health and metabolism.衰老与代谢： 衰老、生殖医学、神经系统健康，以及心血管健康与代谢。
- Translational research: the translation of molecular biology into therapeutics, spanning stem cells and senescence, cancer and neurobiology.转化研究： 分子生物学向治疗学的转化，包括干细胞与细胞衰老、癌发生与神经生物学。
Manuscript types include research papers and reports, reviews, perspectives and letters. The journal is hybrid open access. Taylor & Francis publishes an acceptance rate of about thirty-nine per cent on its official page, together with averages of fifty-eight days from submission to first decision, including editorial desk review, and forty-four days to a post-review decision.稿件类型包括研究论文与报告、综述、观点与通讯。该刊为混合开放获取。泰勒-弗朗西斯官方页面公布其录用率约为百分之三十九，并公布投稿至首次决定平均五十八天（含编辑部桌审）、复审后决定平均四十四天。[1]
History
- Founding (2002): the journal was founded in January 2002 by the small specialist publisher Landes Bioscience in Texas, with Mikhail V. Blagosklonny as founding editor-in-chief, a post he held for more than sixteen years创刊（二〇〇二年）： 本刊于二〇〇二年一月由小型专业出版社兰德斯生物科学创办于得克萨斯州，创刊主编为米哈伊尔·布拉戈斯克隆尼，其执掌编务十六余年；创刊筹备期间编委保罗·纳斯获诺贝尔奖，传为创刊花絮。 the Nobel Prize awarded to board member Paul Nurse during preparations for the launch is a favourite piece of founding lore.[1]
- Publisher transition (2014): the Taylor & Francis Group acquired Landes Bioscience in June 2014, with the journal's masthead completing the switch from 2015 as it entered the group's large journal portfolio.出版方易主（二〇一四年）： 泰勒-弗朗西斯集团于二〇一四年六月收购兰德斯生物科学，刊头自二〇一五年起完成切换，本刊转入该集团大型期刊组合。[2]
- Twenty-fifth anniversary (2026): the journal marked its twenty-fifth anniversary with an editorial in 2026, tracing its growth from tumour cell-cycle work into the wider territories of ageing and metabolism.二十五周年（二〇二六年）： 本刊在二〇二六年发表二十五周年社论，回顾其从肿瘤细胞周期研究起步、逐步扩展至衰老与代谢领域的历程。[3]
- Frequency and positioning: the journal now appears every two weeks, twenty-four issues a year, its official profile stressing the goal of fast publication of outstanding research, with three Nobel laureates on the board as a standing attraction to authors.刊期与定位： 现行每两周一期、每年二十四期，官方简介强调其目标是快速发表杰出研究，编委含三位诺贝尔奖得主是其招揽稿件的重要招牌。[1]
- Metric standing: the 2025 impact factor is 3.9, placing the journal in the third quartile of cell biology and zone three of biology in the Chinese Academy of Sciences ranking.指标走势： 二〇二五年影响因子三点九，在细胞生物学小类列三区，在中科院生物学大类列三区。[4]
Editors
The journal is run by a single editor-in-chief, supported by an assistant to the editor, seven associate editors and an editorial board of about forty members. The publisher posts both acceptance rate and review timing on its official page, a transparency unusual among cell-biology titles.本刊实行单一主编制，配一名主编助理、七名副编辑与约四十人的编辑委员会。出版方在官方页面公布录用率与审稿时长两项指标，在细胞生物学刊物中属于少有的透明做法。[1]
- Gaetano Santulli (editor-in-chief): professor at the CUNY School of Medicine, previously at the Albert Einstein College of Medicine, working on cardiovascular biology, intracellular calcium signalling and metabolic ageing.加埃塔诺·桑图利（现任主编）： 纽约市立大学医学院教授（此前执教阿尔伯特·爱因斯坦医学院），研究方向为心血管生物学、胞内钙信号与代谢衰老。[1]
- Mikhail V. Blagosklonny (founding editor-in-chief): investigator at the Roswell Park Comprehensive Cancer Center, who ran the journal for more than sixteen years and is the leading proponent of the rapamycin-and-ageing hypothesis.米哈伊尔·布拉戈斯克隆尼（创刊主编）： 罗斯威尔帕克综合癌症中心研究员，执掌本刊十六余年，是「雷帕霉素抗衰老」假说的主要倡导者。[1]
- Associate editors: the seven associate editors sit at Imperial College London and at institutions in France, Italy, Spain and the United States, covering cycle regulation, cell death and metabolism.副编辑构成： 七名副编辑分驻帝国理工学院、法国、意大利、西班牙与美国多地，覆盖周期调控、细胞死亡与代谢等方向。[5]